Novo Nordisk's Martin Holst Lange preveiwed the company's obesity pill, while OpenAI launches new initiative to speed up scientific discovery.

Teva Pharmaceuticals gained FDA approval to launch the first generic GLP-1 drug for weight loss, a liraglutide injection based on Saxenda.

President Trump urged pharmaceutical companies to publicly prove that their Covid-19 products work, saying in a Truth Social ...

Israeli drugmaker Teva Pharmaceutical Industries has announced US Food and Drug Administration (FDA) approval and launch of a generic version of Saxenda (liraglutide injection).

In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug market, revolutionizing diabetes and obesity treatment with its ...

Novo Nordisk (NVO), the Danish pharmaceutical leader, has reclaimed its dominance in the GLP-1 market, driven by strategic agility and innovative breakthroughs.

Health Ozempic Maker Novo Nordisk Freezes Hiring Amid Ongoing Struggles The Danish pharmaceutical company has struggled in recent months to meet its lofty sales expectations.

Novo Nordisk stock looks so cheap, any good news at all can make it pop.

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form of liver disease, beating rival Eli Lilly & Co. to the US market ...

10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) is quite the divisive stock among both investors and analysts these days.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them.